Drug intelligence / Profile preview

dermatophagoides pteronyssinus

Development stage
Approved
Lead developer
ALK Abelló
Modality
Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration
Subcutaneous, Sublingual, Intradermal, Intranasal, Inhalation
01

Overview

Dermatophagoides pteronyssinus allergen extract is a biological product derived from the house dust mite species of the same name, used primarily for the diagnosis and treatment of IgE-mediated allergic diseases such as allergic rhinitis, allergic conjunctivitis, and allergic asthma. As a diagnostic agent, it is employed in skin prick testing and provocation tests (nasal or bronchial) to identify hypersensitivity. As a therapeutic agent, it is used in allergen-specific immunotherapy (AIT), administered either subcutaneously (SCIT) or sublingually (SLIT). The mechanism of action involves modulating the immune system to induce long-term tolerance, typically characterized by a shift from a Th2-biased allergic response to a Th1/Treg-mediated tolerant response. This process includes the induction of regulatory T-cells (Tregs), increased production of the anti-inflammatory cytokine IL-10, and the generation of allergen-specific IgG4 antibodies that act as blocking antibodies to prevent IgE-mediated mast cell and basophil degranulation.

Brand names
Alutard SQAquagenGreer Standardized Mite Extract
Other names
Der phouse dust mite extractDermatophagoides pteronyssinus allergen extractD. pteronyssinus
02

Targets

BCR (Immunoglobulin G B Cell Receptor)PAR2 (Protease-activated receptor 2)γδ TCR (T-cell receptor)

Beyond the preview

Go deeper on dermatophagoides pteronyssinus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dermatophagoides pteronyssinus.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call